Thrombogenic properties of prothrombin complex concentrates [letter]
نویسندگان
چکیده
منابع مشابه
Thrombogenic properties of prothrombin complex concentrates.
In a recent paper White et al.’ reported that the thrombogenic properties of prothrombin complex concentrates (PCC) are due to the presence of factors IXa and Xa. The presence of these activated factors, however, was detected indirectly by applying different inhibitors, e.g., a specific seryl reagent, phenylmethylsulfonyl fluoride (PMSF). They concluded that the effect of PMSF is due to the ina...
متن کاملProthrombin complex concentrates: potentially thrombogenic materials and clues to the mechanism of thrombosis in vivo.
Factors affecting the coagulant activity of two different prothrombin complex concentrates have been investigated using a sensitive in vitro assay developed in this laboratory. One concentrate contained substantial amounts of potentially thrombogenic material, while the other, which was deliberately fortified with antithrombin III and heparin during production, was judged to be relatively nonth...
متن کاملPerioperative use of prothrombin complex concentrates.
Prothrombin complex concentrates (PCCs) are purified drug products with hemostatic activity derived from a plasma pool. Today, PCCs contain a given and proportional amount of four non-activated vitamin K-dependent coagulation factors (II, VII, IX, and X), a variable amount of anticoagulant proteins (proteins C and S, and in some antithrombin) and low-dose heparin. In some countries PCC products...
متن کاملProthrombin complex concentrates in warfarin anticoagulation reversal
Anticoagulation is very effective for primary and secondary prevention of thromboembolic events. However, questions persist about the risks and management of over-anticoagulation. The annual incidence of major bleeding in trials and cohort studies has been reported to be between 1.1% and 2.3% in patients treated with warfarin to achieve an international normalized ratio (INR) of 2.0 to 3.0. The...
متن کاملProthrombin Complex Concentrates Use in Intracerebral Hemorrhage.
We would treat with 4-factor PCCs because otherwise—with an INR of 1.9—there is a high risk of further expansion of an already large ICH. Without reversal of the anticoagulant effects of warfarin, the patient’s life is at stake. At age 65 years, he has a reasonable chance to recover from a right-sided ICH if treated early and aggressively. In our eyes, early withdrawal of care is not an option!...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 1977
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood.v50.5.961.961